The value of corticotropin-releasing hormone (CRH) test for differential diagnosis of Cushing’s syndrome | Zendy

Zorana Penezić | Zendy; Miloš Žarković | Zendy; Svetlana Vujović | Zendy; Miomira Ivović | Zendy; Biljana Beleslin | Zendy; Jasmina Ćirić | Zendy; Milka Drezgić | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The value of corticotropin-releasing hormone (CRH) test for differential diagnosis of Cushing’s syndrome

Author(s) -

Zorana Penezić,

Miloš Žarković,

Svetlana Vujović,

Miomira Ivović,

Biljana Beleslin,

Jasmina Ćirić,

Milka Drezgić

Publication year - 2007

Publication title -

srpski arhiv za celokupno lekarstvo

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.135

H-Index - 17

eISSN - 2406-0895

pISSN - 0370-8179

DOI - 10.2298/sarh0702031p

Subject(s) - medicine , endocrinology , basal (medicine) , differential diagnosis , pituitary adenoma , receiver operating characteristic , cushing syndrome , adrenal adenoma , area under the curve , adrenocorticotropic hormone , adenoma , hormone , pathology , diabetes mellitus

Diagnosis and differential diagnosis of Cushing's syndrome (CS) remain considerable challenge in endocrinology. For more than 20 years, CRH has been widely used as differential diagnostic test. Following the CRH administration, the majority of patients with ACTH secreting pituitary adenoma show a significant rise of plasma cortisol and ACTH, whereas those with ectopic ACTH secretion characteristically do not.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research